|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overall, the transient localized expression of IL-15 in the tumour by an oncolytic virus was able to induce stronger anti-tumoral immunity in a murine model of colon carcinoma.
|
22158521 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, in vivo analysis in a lung metastasis tumor mouse model revealed a superior antitumor effect for scFv_RD_IL-15 in comparison with that obtained by an untargeted or RD missing version of IL-15 fusion protein.
|
22491823 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.
|
22565311 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together, these results indicate that expression of IL-15 in the tumor microenvironment may prevent the escape of antigen loss variants and subsequent tumor recurrence by enabling T cells to eliminate cancer cells lacking cognate antigen expression in a locally restricted manner.
|
23637340 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the IL-15 culture prolonged the survival of animals bearing melanoma tumors after adoptive transfer.
|
23931270 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Only among AA women, IL15 rs10833 and IL15RA rs2296135 were associated with ER-positive tumors, and IL12RB1 rs375947, IL15 rs10833 and TGFB1 rs1800469 were associated with ER-negative tumors.
|
23996684 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Delivery of IL-15 plasmid by EP resulted in increased IL-15 expression within the tumor compared to the injection only control.
|
24000979 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An HLA-dependent increase in CD137 expression was observed following incubation of fresh enzyme-digested tumor or ascites in IL-7 and IL-15 cytokines, but not IL-2.
|
24045181 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Animals vaccinated with tumor cells coexpressing IL-15 and IL-15Rα showed greater tumor infiltration with CD8(+) T and natural killer (NK) cells, as well as increased antitumor CD8(+) T-cell responses.
|
24572789 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both rNDV-IL15 and rNDV-IL2 effectively suppressed tumor growth compared with rNDV.
|
24645750 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results delineate chromosomal instability as a mechanism of modulating local cytokine expression in human tumors and underline the major role of IL15.
|
24648340 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral injection of Ad-CCL20-IL-15 into both CT-26 and B16F10 cells resulted in marked reduction of tumor growth in our model.
|
24657179 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recombinant dsNKG2D-IL-15 thus inhibited NKG2D ligand-positive tumor growth effectively by activating lymphocytes.
|
24810637 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that the intratumoral injection of Ad-CCL21-IL-15 into murine colon carcinomas significantly inhibited tumor growth.
|
24838092 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study have shown that CIK cells stimulated with combination of IL-2 and IL-15 displayed improved proliferation capacity and tumor cytotoxicity.
|
25108500 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Precisely because IL-15 can activate natural killer (NK) cells, CD8(+)T cells, and other immune cells, in antitumor therapy, Ad-E2F/IL15 was used in combination with cytotoxic T lymphocytes (CTL) to create a virus that can induce IL-15 gene expression while lysing tumors and stimulating the activity and function of adoptive immune cells.
|
25627006 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared survival curves and tumor formation in IL-15 KO/MT, MT and IL-15 TG/MT groups.
|
25879689 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The IL-12-adjuvanted allogeneic HER2/neu-expressing cell vaccine was still able to delay mammary cancer onset but efficacy in IL-15-lacking mice vanished earlier: all vaccinated IL15KO/NeuT mice developed tumors within 80 weeks of age (median latency of 53 weeks), whereas more than 70 % of vaccinated NeuT mice remained tumor-free up to 80 weeks of age.
|
25997501 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we explored the different effects of IL-15 and IL-2 on tumor-infiltrating (TI) T cells from resected breast tumors.
|
26141233 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data highlight the potential use of human dsNKG2D-IL-15 for tumor therapy.Cellular & Molecular Immunology advance online publication, 14 September 2015; doi:10.1038/cmi.2015.81.
|
26364916 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor morphology observation and growth indexes also showed that IL-15-transfected CIK cells had stronger cytotoxicity to tumor tissue than CIK cells.
|
26503216 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, transfer of the Il-15/sIl-15Rα gene alone, or in combination with gemcitabine chemotherapy, significantly inhibited the tumor growth in these three organs and prolonged median survival time of treated mice by 1.7- and 3.3-fold, respectively.
|
26742578 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
From a biological perspective, it has been demonstrated that HR2A could have a beneficial effect on CRC for many reasons: i) promotion of peri-tumoral lymphocyte growth and improvement of immune response against the tumor, ii) suppression of adhesion molecules which might favor metastasis, iii) anti-angiogenetic activity (reduction of VEGF), iv) increased production of some cytokines which may counteract tumor growth, such as tumor necrosis factor (TNF) alpha, interleukin (IL)-10 and IL-15.
|
26996193 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the treatment of established tumors with the combined therapy of CIK cells and CRAd-CCL21-IL15 resulted in tumor regression.
|
27380620 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, the administration of IL-15 and IL-21 in combination with CART cells in vivo increased their tumor killing capacity.
|
27409425 |
2016 |